SIBN SI-BONE, Inc.
HealthcareAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
3.61
P/S
3.16
EV/EBITDA
-85.13
DCF Value
$40.27
FCF Yield
-0.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
79.6%
Operating Margin
-9.7%
Net Margin
-8.1%
ROE
-9.6%
ROA
-6.9%
ROIC
-9.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $52.6M | $-4.3M | $— |
| Q4 null | $56.4M | $-1.6M | $— |
| FY null | $200.9M | $-18.9M | $— |
| Q3 null | $48.7M | $-4.6M | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$25.25
Target (Median)
$25.50
Target Range
$23.00 - $27.00
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
0.67
SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.